2170616-59-6
2170616-59-6
Chemical Structure
GC813
- CAS No.: 2170616-59-6
- Formula:C22H31ClN3NaO8S
- Molecular Weight:556.00
InChIKey: ZIVZAVLWWUPQGT-FCSMXUNPSA-M
SMILES: O=C(NCC1)[C@@H]1C[C@@H](C(O)S(=O)(O[Na])=O)NC([C@H](CC(C)C)NC(OCCC2=CC(Cl)=CC=C2)=O)=O
Biological Activity: GC813 is a MERS-CoV 3CL protease (3CLpro) and MERS-CoV main protease (Mpro) inhibitor. GC813 can be used for the research of middle east respiratory syndrome[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GC813 | GC813 is a MERS-CoV 3CL protease (3CLpro) and MERS-CoV main protease (Mpro) inhibitor. GC813 can be used for the research of middle east respiratory syndrome. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Galasiti Kankanamalage AC, et al. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element. Eur J Med Chem. 2018 Apr 25;150:334-346. [Content Brief]
- [2]. Gurung AB, et al. In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors. Saudi J Biol Sci. 2020;27(10):2674-2682. [Content Brief]
